

41



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900
NOV 21 2003

RECEIVED

In re Application of:

STREHLKE, Peter, et al.

Examiner: 1624

Serial No.: 10/078,530

Group Art Unit: LIU, Hong

Filed: February 21, 2002

Title: QUINOLINE, ISOQUINOLINE AND PHTHALAZINE DERIVATIVES AS
ANTAGONISTS OF THE GONADOTROPIN-RELEASING HORMONE

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

In response to the Restriction Requirement dated October 15, 2003, Applicants hereby elect with traverse Group I, claim 1-16, drawn to compounds of formula I wherein W=X=Y is -C=C-N-. Applicants traverse the Restriction Requirement on the basis that the Examiner has not established that examining all of the claims in the application would constitute a serious burden (See M.P.E.P. §803).

Applicants also elect with traverse the species of Example 1, namely 6-(4-Acetamidophenoxy)-5-(N-benzyl-N-methylaminomethyl)-1-(2',6'-difluorobenzyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid-ethyl ester. Applicants respectfully submit that the entire scope of the pending claims can be examined without undue burden (see M.P.E.P. §803). In any event, Applicants assume that the examination will proceed in accordance with M.P.E.P. §809.02(c).

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



James E. Ruland, Reg. No. 37,432
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: November 17, 2003
Attorney Docket No.: ZENTAR-0001

JER/jqs
K:\Zentar\1\Response to Restriction Requirement 11-17-03.doc